<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230808059075N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-19</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of  the Effectiveness of Ketamine vs Morphine Sulfate vs Ketamine-Morphine Sulfate in Intertrochanteric Hip Fracture Pain Management</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of  the Effectiveness of Ketamine vs Morphine Sulfate vs Ketamine-Morphine Sulfate in Intertrochanteric Hip Fracture Pain Management of Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72031</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method of assigning people to the studied groups is by using the block classification method. To control the effect of the confounding variable of gender, these changes are considered as classes and then in each class, people will be assigned to treatment groups using the random block method. In order to eliminate the possibility of final allocation by the person who allocates patients to groups, random block method with unequal volume is used. For this purpose, 3 of the blocks include 6 and some 9 permutations. The unit of randomization is individual and the tool used to randomize the order of entry into the study is Excel statistical software, Blinding description: Before enrolling the patient in the study, the consent form to participate in the research plan will be read to them, and if they agree, the patients will participate in the study.
In the injection of drugs, a group of nurses will prepare the prescribed drugs in 5cc syringes according to the pre-designed random block method and will present them to another group of nurses who are responsible for injecting the drugs without informing them of the contents.
The pain level of the patients before the drug injection and at 30, 60, 90 and 120 minutes after the end of the drug infusion will be evaluated based on the VAS scale, the responsibility of evaluating the pain score in all patients will be done by an experienced emergency medicine doctor who He does not know the type of drug prescribed, and finally, the difference in the VAS score before drug administration and the determined times after drug administration will be used as a criterion for evaluating the success of drugs in reducing pain.</study_design>
      <phase>3</phase>
      <hc_freetext>Intertrochanteric hip fracture.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: 0.3 mg/kg of Ketamine (ROTEXMEDICA company) intravenously and 5 cc of intravenous normal saline as a placebo will be infused within 5 minutes. Intervention 2: The second intervention group: 0.1 mg/kg of intravenous Morphine (Darou Pakhsh company) and 5 cc of normal intravenous saline will be infused within 5 minutes as a placebo. Intervention 3: The third intervention group: 0.15 mg/kg of Ketamine (ROTEXMEDICA company) and 0.1 mg/kg of intravenous Morphine (Darou Pakhsh company) will be infused simultaneously within 5 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual data of study participants can be shared after de-identification and information about the main outcome is accessible.

When:
The period of access to the data is from the time of printing the results until 6 months later.

To whom:
Researchers working in all academic and scientific institutions can access documented data.

Conditions:
For similar research studies and data analysis, access to the documents will be provided by requesting through the academic email to the email of the research committee of Lorestan University of Medical Sciences within one week.

Where to obtain:
To access the data by academic email, send a request to the Vice President of Research and Technology of Lorestan University of Medical Sciences at the address research@lums.ac.ir and contact number +986633120172 or fax number +986633120173 and it will be available to you within a week.
You can also contact the contact number +989166296140 and email Maark1375@gmail.com in the name of Mahdi Arkani regarding the data request.

How to obtain:
To access the data by academic email, send a request to the Vice President of Research and Technology of Lorestan University of Medical Sciences at the address research@lums.ac.ir and contact number +986633120172 or fax number +986633120173 and it will be available to you within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahdi Arkani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 24,26 , Banafsheh Alley, Andisheh Phase 2</address>
        <city>Borujerd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6919757413</zip>
        <telephone>+98 66 4230 0652</telephone>
        <email>Maark1375@gmail.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahdi Arkani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 24,26 , Banafsheh Alley, Andisheh Phase 2</address>
        <city>Borujerd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6919757413</zip>
        <telephone>+98 66 4230 0652</telephone>
        <email>Maark1375@gmail.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>There is evidence of femur fracture in the intertrochanteric area in the pelvic x-ray or CT scan of the patient
Be over 65 years old</inclusion_criteria>
      <agemin>65 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients addicted to opioids
Patients with a history of allergy to Morphine or Ketamine
Systolic blood pressure greater than 180 or less than 90 mm Hg
Arterial oxygen saturation less than 90%
Altered state of consciousness
Patients who do not cooperate
Patients with a history of ischemic heart diseases
Patients with a history of kidney diseases
Patients with a history of liver diseases
Patients with a history of obstructive lung diseases
Patients with a history of psychotic diseases
People who have taken painkillers before entering the hospital</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S72.14</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Intertrochanteric fracture of femur</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: 0.3 mg/kg of Ketamine (ROTEXMEDICA company) intravenously and 5 cc of intravenous normal saline as a placebo will be infused within 5 minutes.</i_keyword>
      <i_keyword>The second intervention group: 0.1 mg/kg of intravenous Morphine (Darou Pakhsh company) and 5 cc of normal intravenous saline will be infused within 5 minutes as a placebo.</i_keyword>
      <i_keyword>The third intervention group: 0.15 mg/kg of Ketamine (ROTEXMEDICA company) and 0.1 mg/kg of intravenous Morphine (Darou Pakhsh company) will be infused simultaneously within 5 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score on Visual analogue scale. Timepoint: The pain score of the patients at the beginning of the study and 30, 60, 90, 120 minutes after taking the medicine. Method of measurement: Visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khoram-Abad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-12</approval_date>
        <contact_name>Ethics Committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Ethics Committee in Clinical Research, Lorestan University of Medical Sciences, Shahid Anoushirvan Rezaei Square, Moalem St., Khorramabad, Lorestan Khorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
